Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06750809 · ClinicalTrials.gov registry record · NA
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds
A NA study of Surgical Wound and Trauma Wound, sponsored by Avita Medical.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT06750809 is a NA study of Surgical Wound and Trauma Wound that is active but no longer recruiting, run by Avita Medical. The registered enrollment target is 40 participants, below the 93-participant average among 17 other Surgical Wound trials with a reported enrollment target (57% lower). The trial reports 13 study locations across 12 states.
The verdict
NCT06750809, a NA study of Surgical Wound and Trauma Wound, is active but no longer recruiting, sponsored by Avita Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this study is to compare the cost and clinical outcomes for two temporary dressings (Allograft and PermeaDerm) used in patients that need a skin graft to heal their wound. The researchers will review cost and other treatment results including how well both temporary dressings attach to the skin, how prepared the wound bed is to receive a skin graft, how long it takes for the skin to be ready to receive a skin graft, how well the skin graft takes and any complications. Patients will first have the temporary dressing applied to their wound, then a few days later, a skin graft will be performed. Patients will have photos of their wounds taken throughout the study including at all the clinic check-ups with the last check-up occurring about 8 weeks after treatment.
Conditions Studied
Interventions
- DEVICE PermeaDerm Biosynthetic Wound Matrix
- DEVICE Frozen Human Cadaveric Allograft (FHCA)
Study Locations (13)
Ohio
- Akron Children's Hospital - Akron
- Ohio State University - Columbus
Arizona
- Valleywise Health - Phoenix
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
Georgia
- Grady Memorial - Atlanta
Iowa
- Univ of Iowa - Iowa City
Kansas
- University of Kansas - Kansas City
Kentucky
- Univ of Louisville Burn Center - Louisville
Louisiana
- University Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2026-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06750809
The ClinicalTrials.gov registry entry for NCT06750809 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 93-participant average among 17 other Surgical Wound trials with a reported enrollment target (57% lower). The listed sponsor is Avita Medical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Surgical Wound appearing as the primary indexed condition, and to 2 interventions - of which PermeaDerm Biosynthetic Wound Matrix is the first listed.
NCT06750809 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Ohio, Arizona, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06750809 about?
NCT06750809 is a clinical study titled "Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds". The goal of this study is to compare the cost and clinical outcomes for two temporary dressings (Allograft and PermeaDerm) used in patients that need a skin graft to heal their wound. The researchers will review cost and other treatment results including how well both temporary dressings attach to t...
What is the current status of trial NCT06750809?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-02-21. Estimated completion is 2026-05.
What conditions does trial NCT06750809 study?
This clinical trial studies the following conditions: Surgical Wound, Trauma Wound, Partial-thickness Burn, Autografts, Partial Thickness Wounds.
What interventions are being tested in trial NCT06750809?
The interventions under investigation include: PermeaDerm Biosynthetic Wound Matrix (DEVICE), Frozen Human Cadaveric Allograft (FHCA) (DEVICE).
Who is sponsoring clinical trial NCT06750809?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06750809 being conducted?
This trial has 13 study locations across Arizona, District of Columbia, Georgia, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Versus Delayed Bathing of Orthopaedic Surgical Wounds
RECRUITING · NA
-
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
ACTIVE NOT RECRUITING · NA
-
Influence of Sun Protection and Linear Repair of Cutaneous Surgical Defects
ACTIVE NOT RECRUITING · NA
-
Suture Closure Trial
ACTIVE NOT RECRUITING · NA
-
RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)
COMPLETED · NA
-
Continuous Diffusion of Oxygen Treatment for Incision Wounds
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.